Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot

LAKE FOREST, Ill., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) today announced that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for its novel injectable formulation of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news